Challenges and Innovations with Prefilled Syringes - Market considerations and new technologies must be recognized to achieve the full benefits of manufacturing prefilled syringes. - BioPharm

ADVERTISEMENT

Challenges and Innovations with Prefilled Syringes
Market considerations and new technologies must be recognized to achieve the full benefits of manufacturing prefilled syringes.


BioPharm International Supplements
Volume 24, Issue 9, pp. s14-s18

MANUFACTURING CHALLENGES


Prefilled syringes’ success
Biotech products, in particular, provide a number of unique manufacturing challenges compared with big therapeutic classes, such as anticoagulants and vaccines. The trend towards readytouse delivery systems combined with the decreasing manufacturing volume associated with biotech products and more targeted therapies poses an efficiency challenge. Batch sizes are typically smaller, requiring potential innovation and manufacturing optimization to provide sustainable value.


Extractables and leachables analysis
For CMOs, there are also complexities related to global regulatory compliance because there are marked differences in the expectations and best practices of key regulatory agencies. For example, specific structural changes needed for one client to ensure regulatory compliance may impact others using the same manufacturing line. Finding appropriate solutions to accommodate the broad spectrum of client and regulatory requirements is an intricate responsibility of utmost importance.


The growth of autoinjectors
As with other sterile filling, such as vials, another challenge that can arise is the need to calibrate automated inspection equipment to meet the standards of multiple regional regulatory agencies, as well as client expectations. There is also often a lack of validated data to adequately handle product physico–chemical limitations, such as air and light sensitivity, time-out from refrigeration, shearing concerns, and others.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Lundbeck CEO Resigns Due to Code of Conduct Breach
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Janssen Partners with Transposagen Biopharmaceuticals for CAR-T Therapies
November 24, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here